alpha1-PDX

alpha1-PDX (alpha1-antitrypsin Portland variant) is a bioengineered serine proteinase inhibitor (serpin) derived from human alpha1-antitrypsin. It was specifically engineered to contain a minimal furin consensus sequence (Arg-X-X-Arg) in its reactive site loop, making it a potent and selective inhibitor of the proprotein convertase furin (Ki = 0.6 nM). Furin is a key endoprotease involved in the proteolytic activation of numerous pathogenic molecules, including viral envelope glycoproteins (e.g., HIV-1 gp160), bacterial toxins (e.g., Pseudomonas exotoxin A), and various growth factors and receptors involved in cancer progression. alpha1-PDX acts as a suicide inhibitor, forming a stable, covalent complex with furin and preventing the processing of its substrates. While it has been extensively studied in preclinical research for its ability to block viral replication and tumor cell invasiveness, it is currently utilized primarily as a research-use-only (RUO) reagent and is not in clinical development.

Other names

alpha1-antitrypsin Portlandalpha-1-antitrypsin Portlandalpha 1-antitrypsin Portlandalpha1-antitrypsin PDXalpha-1-antitrypsin PDXalpha 1-antitrypsin PDXalpha1-antitrypsin Portland variantalpha-1-antitrypsin Portland variantalpha 1-antitrypsin Portland variantalpha-1-PDXalpha1-PDXalpha 1-PDX